Elias A. Halabi

Elias A. Halabi

Auto-generated profile, based on publicly available information

Elias A. Halabi

Center for Systems Biology Massachusetts General Hospital Harvard Medial School 185 Cambridge Street, CPZN 5206 02114 Boston MA USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2022 in Advanced Materials
Verified
Journal Article
Open access
SLSophie Lugani
Sophie Lugani
EHElias A. Halabi
Elias A. Halabi
JOJuhyun Oh
Juhyun Oh
RKRainer H. Kohler
Rainer H. Kohler
HPHannah M. Peterson
Hannah M. Peterson
RWRalph Weissleder
Ralph Weissleder
Myeloid cells are abundant, create a highly immunosuppressive environment in glioblastoma (GBM), and thus contribute to poor immunotherapy responses. Based on the hypothesis that small molecules can be used to stimulate myeloid cells to elicit anti‐tumor effector functions, a synthetic nanoparticle approach is developed to deliver dual NF‐kB pathway‐inducing agents into these cells via systemic administration. Synthetic, cyclodextrin‐adjuvant nanoconstructs (CANDI) with high affinity for tumor‐associated myeloid cells are dually loaded with a TLR7 and 8 (Toll‐like receptor, 7 and 8) agonist (R848) and a cIAP (cellular inhibitor of apoptosis protein) inhibitor (LCL‐161) to dually activate these myeloid cells. Here CANDI is shown to: i) readily enter the GBM tumor microenvironment (TME) and accumulate at high concentrations, ii) is taken up by tumor‐associated myeloid cells, iii) potently synergize payloads compared to monotherapy, iv) activate myeloid cells, v) fosters a “hot” TME with high levels of T effector cells, and vi) controls the growth of murine GBM as mono‐ and combination therapies with anti‐PD1. Multi‐pathway targeted myeloid stimulation via the CANDI platform can efficiently drive anti‐tumor immunity in GBM.

5 April 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
EHElias A. Halabi
Elias A. Halabi
RWRalph Weissleder
Ralph Weissleder

12 October 2023 in ACS Nano
Verified
Journal Article
Closed access
IFIna R. Fredrich
Ina R. Fredrich
EHElias A. Halabi
Elias A. Halabi
RKRainer H. Kohler
Rainer H. Kohler
XGXinying Ge
Xinying Ge
CGChristopher S. Garris
Christopher S. Garris
RWRalph Weissleder
Ralph Weissleder

3 May 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
EHElias A. Halabi
Elias A. Halabi
IGIsabel Gessner
Isabel Gessner
KYKatherine S. Yang
Katherine S. Yang
JKJae-Jun Kim
Jae-Jun Kim
RJRupsa Jana
Rupsa Jana
RWRalph Weissleder
Ralph Weissleder
Multiplexed bead assays for solution‐phase biosensing often encounter cross‐over reactions during signal amplification steps, leading to unwanted false positive and high background signals. Current solutions involve complex custom‐designed and costly equipment, limiting their application in simple laboratory setup. In this study, we introduce a straightforward protocol to adapt a multiplexed single‐bead assay to standard fluorescence imaging plates, enabling the simultaneous analysis of thousands of reactions per plate. This approach focuses on the design and synthesis of bright fluorescent and magnetic microspheres (MagSiGlow) with multiple fluorescent wavelengths serving as unique detection markers. The imaging‐based, single‐bead assay, combined with a scripted algorithm, allows the detection, segmentation, and co‐localization on average of 7500 microspheres per field of view across five imaging channels in less than one second. We demonstrate the effectiveness of this method with remarkable sensitivity at low protein detection limits (100 pg/mL). This technique showed over 85 % reduction in signal cross‐over to the solution‐based method after the concurrent detection of tumor‐associated protein biomarkers. This approach holds the promise of substantially enhancing high throughput biosensing for multiple targets, seamlessly integrating with rapid image analysis algorithms.

9 October 2023 in Advanced Science
Verified
Journal Article
Open access
RDRiddha Das
Riddha Das
EHElias A. Halabi
Elias A. Halabi
IFIna R. Fredrich
Ina R. Fredrich
JOJuhyun Oh
Juhyun Oh
HPHannah M. Peterson
Hannah M. Peterson
RWRalph Weissleder
Ralph Weissleder
The efficient activation of professional antigen‐presenting cells—such as dendritic cells (DC)—in tumors and lymph nodes is critical for the design of next‐generation cancer vaccines and may be able to provide anti‐tumor effects by itself through immune stimulation. The challenge is to stimulate these cells without causing excessive toxicity. It is hypothesized that a multi‐pronged combinatorial approach to DC stimulation would allow dose reductions of innate immune receptor‐stimulating TLR3 agonists while enhancing drug efficacy. Here, a hybrid lipid nanoparticle (LNP) platform is developed and tested for double‐stranded RNA (polyinosinic:polycytidylic acid for TLR3 agonism) and immune modulator (L‐CANDI) delivery. This study shows that the ≈120 nm hybrid nanoparticles‐in‐nanoparticles effectively eradicate tumors by themselves and generate long‐lasting, durable anti‐tumor immunity in mouse models.

11 February 2024 in Advanced Science
Verified
Journal Article
Open access
NENoah Enbergs
Noah Enbergs
EHElias A. Halabi
Elias A. Halabi
AGAnne‐Gaëlle Goubet
Anne‐Gaëlle Goubet
KSKelton Schleyer
Kelton Schleyer
IFIna R. Fredrich
Ina R. Fredrich
RWRalph Weissleder
Ralph Weissleder
Tumor‐associated macrophages (TAM) are a diverse population of myeloid cells that are often abundant and immunosuppressive in human cancers. CXCL9 Hi TAM has recently been described to have an antitumor phenotype and is linked to immune checkpoint response. Despite the emerging understanding of the unique antitumor TAM phenotype, there is a lack of TAM‐specific therapeutics to exploit this new biological understanding. Here, the discovery and characterization of multiple small‐molecule enhancers of chemokine ligand 9 (CXCL9) and their targeted delivery in a TAM‐avid systemic nanoformulation is reported. With this strategy, it is efficient encapsulation and release of multiple drug loads that can efficiently induce CXCL9 expression in macrophages, both in vitro and in vivo in a mouse tumor model. These observations provide a window into the molecular features that define TAM‐specific states, an insight a novel therapeutic anticancer approach is used to discover.